Abstract: Glycosylated indolocarbazoles, method for obtaining same and uses thereof. This invention relates to rebeccamycin and staurosporine derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and the production of rebeccamycin and staurosporine derivatives. The invention also relates to bacterial strains that are of use for the production of rebeccamycin and staurosporine derivatives. Lastly, the rebeccamycin and staurosporine derivatives described herein are applicable to the field of human health, specifically for manufacturing drugs that are of use in the treatment of tumour, neurological and inflammatory diseases.

Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica milliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

Abstract: The present application relates to an oral formulation of amphotericin B and other therapeutic agents, which formulation comprises one or more fatty acid glycerol esters and one or more PEG modified phospholipids or fatty acid esters. The formulation provides enhanced bioavailability and/or increased stability of the therapeutic agent at the low pH found in gastric fluid.

Abstract: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.

Abstract: The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinary tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions adapted for direct instillation into the bladder and/or for systemic administration are provided comprised of therapeutic amounts of: chondroitin sulfate in combination with hyaluronan (hyaluronic acid) are provided. Compositions adapted for direct instillation into the bladder and/or for systemic administration are also provided comprised of therapeutic amounts of: chondroitin sulfate, hyaluronan (hyaluronic acid) and N-acetyl D-glucosamine.

Abstract: An object of the present invention is to provide a uronic acid-containing glucan or a modified product thereof. The glucuronic acid-containing glucan of the present invention is a glucuronic acid-containing glucan in which a glucuronic acid residue is bound to at least one non-reducing end of a glucan, and the glucan is a branched ?-1,4 glucan or a linear ?-1,4 glucan. The glucuronic acid-containing glucan of the present invention can be provided by allowing ?-glucan phosphorylase derived from Aquifex aeolicus VF5 to act on glucuronic acid-1-phosphate to thereby transfer a glucuronic acid residue to the non-reducing end of the receptor glucan.

Abstract: Disclosed is a method for separating anthocyanins depleted in phenolic mixture content from fruits or vegetables feedstock containing anthocyanins and phenolic mixtures. The first step is to contact the feedstock with a cation-exchange resin at low pH for a time period effective for the resin to selectively bind with the anthocyanins. Next, the non-bound phenolic mixture is separated from the resin for recovery. The bound resin is subjected to solvent wash to release the anthocyanins for recovery.

Abstract: The present invention relates to a composition derived from the hydrolysate of plant containing crocin or the derivatives thereof. The composition includes a significant amount of crocetin monoester. The present invention also provides a method to hydrolyze crocin existing in a plant extract, and further relates to the use.

Abstract: Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.

Abstract: A novel method and composition for treating vitamin B12 deficiency mammals that fail to respond to oral vitamin B12 therapy.

Abstract: The invention relates to the use of certain derivatives of D-mannopyranoside for controlling angiogenesis. These compounds have a pro-angiogenic activity, and can particularly be used for preparing a pharmaceutical composition for treating cardiovascular diseases or for treating muscular atrophy. The invention also relates to certain D-mannopyranoside derivatives, to a pharmaceutical or cosmetic composition containing said derivatives, and to the use of such a cosmetic composition for preventing and/or treating hair loss.

Abstract: Veterinary compositions which provide a high-dose of doramectin or a high-dose veterinary combination composition which comprises doramectin and one or more other antiparasitic agents is disclosed. The compositions provide both antiparasitic efficacy and a significantly reduced withhold time.

Abstract: The present invention relates to an improved anti-fungal composition, to a process for preparing it and to its use as a preservative.

Abstract: Compositions comprising at least one bactericidal antibiotic from the group of macrolides and a non-steroid anti-inflammatory with selective inhibiting activity for cycloxygenase 2 (COX-2). The present invention also refers to a dosage form of said compositions, as well as a method to treat pet animals, particularly dogs and cats. Compositions of the present invention are particularly useful for administration to provide animals with dosages of about 1.0 to 50 mg of compound A/kg of body weight of the animal and about 0.05 to 5.0 mg of compound B/kg of body weight of the animal, being compound A preferably azithromycin and compound B, meloxicam.

Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.

Abstract: The present invention provides the use of icariside II or extract comprising thereof in manufacture of products for preventing or treating male or female sexual dysfunction, in particular, the use for improving pathological or organical changes in erectile tissues of patients with erectile dysfunction.

Abstract: Provided is a composition for prophylaxis or treatment of an eye disease comprising a compound represented by General Formula I: S-(MS)p-(MS)q??General Formula I wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue. The compound used as the active ingredient inhibits expression of MMP-9 and inflammation-mediated cytokines (IL-1?, TNF-?, etc.) in corneal epithelial cells and inhibits VEGF-mediated VEGFR-2 activation in human retinal endothelial cells (HREC), thereby exhibiting prophylactic or therapeutic activity for eye diseases such as dry eye syndrome, inflammatory eye disease, neovascularization-associated eye disease and side effects of wearing of contact lenses. Also, because it has no cytotoxicity or skin side effect, the provided composition may be safely used as a pharmaceutical composition, a neutraceutical composition or a food composition.

Abstract: The invention provides compositions and methods that employ compounds that can stimulate proliferation of fibroblasts or keratinocytes and/or stimulate production of collagen by fibroblasts. These compositions and methods are useful for treating gum- and skin-related conditions.

Abstract: Described are methods for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, among other uses, may be used to make macrolides. Also described are solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.

Abstract: Disclosed is a cytoprotective composition comprising hesperidin or a pharmaceutically acceptable salt thereof as an active ingredient. Having the ability to protect cells from radiation-induced injuries in addition to being non-toxic to cells, hesperidin in accordance with the present invention can be used as an active cytoprotective agent.